- Home
- WAL vs EXEL Comparison
WAL vs EXEL Comparison
Compare WAL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAL
- EXEL
- Stock Information
- Founded
- WAL 1994
- EXEL 1994
- Country
- WAL United States
- EXEL United States
- Employees
- WAL N/A
- EXEL N/A
- Industry
- WAL Major Banks
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WAL Finance
- EXEL Health Care
- Exchange
- WAL Nasdaq
- EXEL Nasdaq
- Market Cap
- WAL 9.3B
- EXEL 9.4B
- IPO Year
- WAL 2005
- EXEL 2000
- Fundamental
- Price
- WAL $74.90
- EXEL $37.10
- Analyst Decision
- WAL Strong Buy
- EXEL Buy
- Analyst Count
- WAL 15
- EXEL 18
- Target Price
- WAL $98.07
- EXEL $37.24
- AVG Volume (30 Days)
- WAL 1.2M
- EXEL 2.9M
- Earning Date
- WAL 04-17-2025
- EXEL 04-29-2025
- Dividend Yield
- WAL 1.97%
- EXEL N/A
- EPS Growth
- WAL 8.41
- EXEL 170.77
- EPS
- WAL 7.09
- EXEL 1.76
- Revenue
- WAL $3,016,200,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- WAL $13.49
- EXEL $5.45
- Revenue Next Year
- WAL $10.02
- EXEL $10.32
- P/E Ratio
- WAL $10.87
- EXEL $21.14
- Revenue Growth
- WAL 17.96
- EXEL 18.49
- 52 Week Low
- WAL $53.75
- EXEL $20.14
- 52 Week High
- WAL $98.10
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- WAL 34.74
- EXEL 56.85
- Support Level
- WAL $71.58
- EXEL $36.63
- Resistance Level
- WAL $87.68
- EXEL $40.02
- Average True Range (ATR)
- WAL 3.35
- EXEL 1.12
- MACD
- WAL -1.31
- EXEL -0.10
- Stochastic Oscillator
- WAL 22.27
- EXEL 41.79
About WAL Western Alliance Bancorporation (DE)
Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.